Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 23, 2024 08:00 ET
|
Vivos Therapeutics, Inc
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
November 14, 2024 16:05 ET
|
Vivos Therapeutics, Inc
Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos...
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
November 13, 2024 17:00 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
October 08, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and...
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
September 19, 2024 07:00 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
September 18, 2024 07:00 ET
|
Vivos Therapeutics, Inc
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now...
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 14, 2024 16:05 ET
|
Vivos Therapeutics, Inc
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting...
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
August 14, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
June 27, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
June 12, 2024 07:30 ET
|
Vivos Therapeutics, Inc
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment...